Literature DB >> 17146397

Cochlear implants for DFNA17 deafness.

Michael S Hildebrand1, Michelle G de Silva, R J McKinlay Gardner, Elizabeth Rose, Carolyn A de Graaf, Melanie Bahlo, Hans-Henrik M Dahl.   

Abstract

BACKGROUND: Nonsyndromic autosomal-dominant, adult-onset sensorineural hearing loss resulting from DFNA17 was described in a single American kindred in 1997, and the causative gene was subsequently identified as MYH9.
OBJECTIVE: The objective of this study was to report clinical and genetic analyses of an Australian family with nonsyndromic adult-onset sensorineural hearing loss.
METHODS: The clinical presentation of the family was detailed and identification of the causative gene was conducted by SNP genotyping and direct sequencing.
RESULTS: Sequence analysis of the MYH9 gene revealed the same missense mutation as in the original DFNA17 family. We are not aware of a link between the two kindreds, making the present one only the second DFNA17 family to be reported.
CONCLUSIONS: One important point of clinical relevance is the excellent outcome with cochlear implants in the Australian family compared with a "poor" response in the American family. Thus, cochlear implants should be strongly considered for clinical management of patients with DFNA17 deafness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17146397     DOI: 10.1097/01.mlg.0000242089.72880.f8

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

1.  Prediction of cochlear implant performance by genetic mutation: the spiral ganglion hypothesis.

Authors:  Robert W Eppsteiner; A Eliot Shearer; Michael S Hildebrand; Adam P Deluca; Haihong Ji; Camille C Dunn; Elizabeth A Black-Ziegelbein; Thomas L Casavant; Terry A Braun; Todd E Scheetz; Steven E Scherer; Marlan R Hansen; Bruce J Gantz; Richard J H Smith
Journal:  Hear Res       Date:  2012-08-28       Impact factor: 3.208

2.  MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis.

Authors:  Karina Althaus; Andreas Greinacher
Journal:  Transfus Med Hemother       Date:  2010-09-15       Impact factor: 3.747

3.  Ripor2 is involved in auditory hair cell stereociliary bundle structure and orientation.

Authors:  Oscar Diaz-Horta; Clemer Abad; Filiz Basak Cengiz; Guney Bademci; Pat Blackwelder; Katherina Walz; Mustafa Tekin
Journal:  J Mol Med (Berl)       Date:  2018-10-03       Impact factor: 4.599

4.  Localization in stereocilia, plasma membrane, and mitochondria suggests diverse roles for NMHC-IIa within cochlear hair cells.

Authors:  Anil K Lalwani; Graham Atkin; Yan Li; Jennifer Y Lee; Dean E Hillman; Anand N Mhatre
Journal:  Brain Res       Date:  2008-01-03       Impact factor: 3.252

5.  c.G2114A MYH9 mutation (DFNA17) causes non-syndromic autosomal dominant hearing loss in a Brazilian family.

Authors:  Vitor G L Dantas; Karina Lezirovitz; Guilherme L Yamamoto; Carolina Fischinger Moura de Souza; Simone Gomes Ferreira; Regina C Mingroni-Netto
Journal:  Genet Mol Biol       Date:  2014-11-14       Impact factor: 1.771

6.  Cochlear implantation is safe and effective in patients with MYH9-related disease.

Authors:  Alessandro Pecci; Eva J J Verver; Nicole Schlegel; Pietro Canzi; Carlos M Boccio; Helen Platokouki; Eike Krause; Marco Benazzo; Vedat Topsakal; Andreas Greinacher
Journal:  Orphanet J Rare Dis       Date:  2014-06-30       Impact factor: 4.123

7.  Comprehensive Etiologic Analyses in Pediatric Cochlear Implantees and the Clinical Implications.

Authors:  Chee-Yee Lee; Pei-Hsuan Lin; Cheng-Yu Tsai; Yu-Ting Chiang; Hong-Ping Chiou; Ko-Yin Chiang; Pei-Lung Chen; Jacob Shu-Jui Hsu; Tien-Chen Liu; Hung-Pin Wu; Chen-Chi Wu; Chuan-Jen Hsu
Journal:  Biomedicines       Date:  2022-07-31

8.  Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders.

Authors:  Béatrice Saposnik; Sylvie Binard; Odile Fenneteau; Alan Nurden; Paquita Nurden; Marie-Françoise Hurtaud-Roux; Nicole Schlegel
Journal:  Mol Genet Genomic Med       Date:  2014-02-07       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.